Skip to content

Released Feb 24, 2026, after the close

10-K filed Mar 16, 2026, 75 days after period end · 0001193125-26-108326

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$23.80Mderived+2,573.6% vs Q4 2024+21.7% vs Q3 2025
Net Income$19.28MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$11,382,000N/M
Operating Incomederived-$24,644,000N/M
Operating Cash Flowderived-$1,190,000N/M
Free Cash Flowderived-$1,666,000N/M
Margins · derived
Gross margin47.8%+250.6 pt vs Q4 2024
Operating margin-103.6%+1058.6 pt vs Q4 2024
Net margin81.0%+3909.4 pt vs Q4 2024

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Revenue$23.80M$890.00K$28.19M$27.02M
Net Income$19.28M-$34.07M-$19.78M-$20.85M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR